一名患有近视性脉络膜新生血管的患者在玻璃体内注射贝伐单抗后发生黄斑裂孔。
Macular hole formation after intravitreal bevacizumab administration in a patient with myopic choroidal neovascularization.
作者信息
Miura Masahiro, Iwasaki Takuya, Goto Hiroshi
机构信息
From the *Department of Ophthalmology, Tokyo Medical University, Ibaraki Medical Center, Ibaraki, Japan; and †Department of Ophthalmology, Tokyo Medical University, Tokyo, Japan.
出版信息
Retin Cases Brief Rep. 2011 Spring;5(2):149-52. doi: 10.1097/ICB.0b013e3181cd1da1.
PURPOSE
The purpose of this study was to report a case of macular hole formation in a patient with myopic choroidal neovascularization (CNV), who was administered intravitreal bevacizumab.
METHODS
A 55-year-old woman with high myopia presented with a sudden decrease in vision in her right eye. Optical coherence tomography imaging showed subfoveal type 2 CNV and a preretinal structure with vitreomacular traction. The patient received intravitreal bevacizumab treatment for the CNV.
RESULTS
Four weeks after the second intravitreal bevacizumab injection, regression of CNV and formation of a macular hole were confirmed from the findings of the optical coherence tomography image. The patient was followed up without further treatment. Six months after the second intravitreal bevacizumab injection, the macular hole closed spontaneously, and visual acuity improved in her right eye.
CONCLUSION
Intravitreal bevacizumab is a powerful modality in the management of myopic CNV; however, the possibility of infrequent complication should be considered.
目的
本研究旨在报告1例患有近视性脉络膜新生血管（CNV）的患者在接受玻璃体内注射贝伐单抗后出现黄斑裂孔形成的病例。
方法
一名55岁的高度近视女性右眼视力突然下降。光学相干断层扫描成像显示黄斑下2型CNV以及伴有玻璃体黄斑牵引的视网膜前结构。该患者接受了玻璃体内注射贝伐单抗治疗CNV。
结果
在第二次玻璃体内注射贝伐单抗四周后，通过光学相干断层扫描图像的结果证实了CNV的消退和黄斑裂孔的形成。该患者未接受进一步治疗并进行随访。在第二次玻璃体内注射贝伐单抗六个月后，黄斑裂孔自发闭合，右眼视力提高。
结论
玻璃体内注射贝伐单抗是治疗近视性CNV的有效方法；然而，应考虑罕见并发症的可能性。
Zotero 插件